Afficher la notice abrégée

dc.rights.licenseopenen_US
dc.contributor.authorDURAND, Pauline
dc.contributor.authorPOTTIER, Valérie
dc.contributor.authorMESGUICH, Charles
dc.contributor.authorDEBORDEAUX, Frédéric
hal.structure.identifierImmunology from Concept and Experiments to Translation = Immunologie Conceptuelle, Expérimentale et Translationnelle [ImmunoConcept]
dc.contributor.authorLAZARO, Estibaliz
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorVIALLARD, Jean-François
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorRIVIÈRE, Etienne
dc.date.accessioned2023-07-18T07:36:08Z
dc.date.available2023-07-18T07:36:08Z
dc.date.issued2023-05-30
dc.identifier.issn2162-3619en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/183411
dc.description.abstractEnThrombocytopenia occurs in 60% of patients with myelodysplastic syndromes (MDS), increasing the risk of life-threatening haemorrhage in this population of mainly old patients with comorbidities. However, data are scare regarding immune thrombocytopenia (ITP) secondary to MDS. We analyzed the utility of indium-111 platelet scintigraphy (IPS) to better characterize the mechanisms of thrombocytopenia in 21 adult patients with MDS. Adult patients with a definite diagnosis of MDS according to the international criteria who underwent IPS between 2009 and 2018 because of an increased bleeding risk were retrospectively selected. Autologous 111Indium platelet labelling was performed with a technique similar to that described previously using a standardized method. Platelet lifespan ≤ 6 days identified patients with peripheral platelet destruction. Taking into account the response to ITP-directed therapies after IPS, the sensitivity, specificity, and positive and negative predictive values of IPS were 100%, 84.6%, 80%, and 100%, respectively. We show that IPS can be a useful tool to identify the mechanism and guide treatment of a chronic thrombocytopenia increasing the bleeding risk in patients with MDS.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectArticle clinique
dc.subject.enImmune thrombocytopenia
dc.subject.enIndium-111 platelet scintigraphy
dc.subject.enMyelodysplastic syndrome
dc.title.enUtility of indium-111 platelet scintigraphy for understanding the mechanism of thrombocytopenia associated with myelodysplastic syndromes and chronic myelomonocytic leukemia.
dc.title.alternativeExp Hematol Oncolen_US
dc.typeArticle de revueen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed37254182en_US
bordeaux.journalExperimental Hematology & Oncologyen_US
bordeaux.page50en_US
bordeaux.volume12en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04164130
hal.version1
hal.date.transferred2023-07-18T07:36:11Z
hal.popularnonen_US
hal.audienceInternationaleen_US
hal.exporttrue
workflow.import.sourcepubmed
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Experimental%20Hematology%20&%20Oncology&rft.date=2023-05-30&rft.volume=12&rft.issue=1&rft.spage=50&rft.epage=50&rft.eissn=2162-3619&rft.issn=2162-3619&rft.au=DURAND,%20Pauline&POTTIER,%20Val%C3%A9rie&MESGUICH,%20Charles&DEBORDEAUX,%20Fr%C3%A9d%C3%A9ric&LAZARO,%20Estibaliz&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée